All Drug Discovery Processes articles – Page 32
-
ArticleNew cell therapy model accelerates cancer treatment development
CTMC, a joint venture between Resilience + MD Anderson Cancer Center, is transforming cancer treatment with faster, more efficient cell therapy development - learn how they’re doing it.
-
NewsUC Davis researchers achieve total synthesis of ibogaine
UC Davis researchers achieve a breakthrough in synthesising ibogaine, enabling safer drug development for addiction and depression treatment.
-
NewsThe immune cells that fuel food allergies
A new study reveals how specific immune cells contribute to the exaggerated immune response in food allergies, offering hope for improved treatments in the future.
-
ArticleNew study links type 2 diabetes to accelerated cognitive decline
Study reveals how type 2 diabetes accelerates cognitive decline by damaging white matter in the brain. Sam Hashemi at Prenuvo explains how advanced AI and whole-body MRI technology are opening new possibilities for early intervention.
-
NewsAzenta's BioArc Ultra powers UK research
UK Biocentre has significantly expanded its sample storage capacity with the addition of Azenta's BioArc Ultra, adding space for 16 million more samples to support vital health research.
-
NewsRestoring the gut: VE303's strategy for C. diff relief
A new publication in Nature Medicine highlights the potential of VE303 for preventing recurrent C. difficile infection, detailing its impact on the gut microbiome and immune response.
-
ArticlePromising Alzheimer’s drug earns FDA fast-track designation
Posdinemab, being investigated by Johnson & Johnson, has received FDA fast-track status. Hear from Dr Fiona Elwood as she explains how Johnson & Johnson’s precision medicine approach could transform Alzheimer’s treatment.
-
NewsAI designs peptides for 'undruggable' diseases
A new AI-powered approach is tackling the challenge of 'undruggable' diseases by designing peptides that can bind to and destroy previously untreatable proteins.
-
NewsITM-11 boosts survival in neuroendocrine tumour trial
A new targeted radiotherapy offers hope for patients with rare neuroendocrine tumours, demonstrating a significant improvement in progression-free survival in a key clinical trial.
-
NewsCoherus announces positive Phase II results for liver cancer treatment
Coherus BioSciences shared final data from its Phase II trial of casdozokitug, showing a 17.2 percent complete response rate in liver cancer patients.
-
NewsGlox Therapeutics secures £500K to develop antibiotics for cystic fibrosis
Glox Therapeutics has received a portion of a £3 million fund to combat antimicrobial resistance in cystic fibrosis patients.
-
ArticleCilta-cel: A new era in multiple myeloma treatment
New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the potential for long-term remission.
-
NewsFirst patient enrolled in fostamatinib trial for sickle cell disease
Rigel Pharmaceuticals has announced the enrolment of the first patient in a Phase I trial evaluating fostamatinib for sickle cell disease.
-
NewsInternational partnership to tackle aggressive adrenal cancer
Cancer Research UK, Cytovation, and the Norwegian Cancer Society have teamed up to advance the treatment of adrenocortical carcinoma (ACC). The collaboration will support the Phase II clinical trial of Cytovation’s innovative therapy, CY-101.
-
ArticleNew study explores safer antidepressants for pregnant women
A new study suggests that targeting serotonin in the gut, rather than the brain, could lead to antidepressants with fewer side effects.
-
NewsThe Michael J Fox Foundation for Parkinson’s Research awards grant to Grifols for pioneering study
Grifols has received a $21 million grant from The Michael J. Fox Foundation to fund a pioneering study aimed at identifying early biomarkers for Parkinson's disease (PD).
-
NewsUVA’s computer models target antibiotics to combat resistance
Researchers at the University of Virginia School of Medicine have developed computer models to create more targeted antibiotics. This approach aims to fight antibiotic resistance by focusing on specific bacteria in different parts of the body, reducing the reliance on broad-spectrum antibiotics.
-
NewsBio-Rad introduces mixed-mode resin for biomolecule purification
Bio-Rad has launched Nuvia wPrime 2A Media, a scalable resin designed for biomolecule purification in research and biotherapeutic applications.
-
ArticleFDA’s Project Optimus: A new era in oncology drug dosing
Explore how FDA’s Project Optimus is reshaping oncology drug dosing strategies, with insights on precision medicine, adaptive trial designs, and the role of CROs in optimising patient outcomes.
-
NewsRett syndrome discovery could lead to better treatments
Researchers have identified early molecular changes in Rett syndrome that could lead to improved treatments for the condition.